ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för saracatinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

32 träffar

Bibliografisk träff 2021-06-22

The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.

Yun HS, Lee J, Kil WJ, Kramp TR, Tofilon PJ, Camphausen K.

Mol Cancer Ther · research support, n.i.h., intramural; research-article; journal article · DOI 10.1158/1535-7163.mct-20-0883

Bibliografisk träff 2021-06-01

Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.

Sharma S, Carlson S, Gregory-Flores A, Hinojo-Perez A, Olson A, Thippeswamy T.

Neurobiol Dis · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.nbd.2021.105410

Bibliografisk träff 2021-04-28

Genetic deletion of endothelial microRNA-15a/16-1 promotes cerebral angiogenesis and neurological recovery in ischemic stroke through Src signaling pathway.

Sun P, Ma F, Xu Y, Zhou C, Stetler RA, Yin KJ.

J Cereb Blood Flow Metab · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1177/0271678x211010351

Bibliografisk träff 2021-04-22

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva.

Williams E, Bagarova J, Kerr G, Xia DD, Place ES, Dey D, Shen Y, Bocobo GA, Mohedas AH, Huang X, Sanderson PE, Lee A, Zheng W, Economides AN, Smith JC, Yu PB, Bullock AN.

JCI Insight · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1172/jci.insight.95042

Bibliografisk träff 2021-02-18

Proteasome regulation by reversible tyrosine phosphorylation at the membrane.

Chen L, Zhang Y, Shu X, Chen Q, Wei T, Wang H, Wang X, Wu Q, Zhang X, Liu X, Zheng S, Huang L, Xiao J, Jiang C, Yang B, Wang Z, Guo X.

Oncogene · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41388-021-01674-z

Bibliografisk träff 2021-01-15

Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice.

Luo XM, Zhao J, Wu WY, Fu J, Li ZY, Zhang M, Lu J.

BMC Neurosci · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12868-020-00606-z

Bibliografisk träff 2021-01-07

ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib.

Hildebrandt S, Kampfrath B, Fischer K, Hildebrand L, Haupt J, Stachelscheid H, Knaus P.

Stem Cell Rev Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s12015-020-10103-9

Bibliografisk träff 2020-07-21

Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.

Yadikar H, Torres I, Aiello G, Kurup M, Yang Z, Lin F, Kobeissy F, Yost R, Wang KK.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0224952

Bibliografisk träff 2020-07-19

Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells.

Chiu LY, Hsin IL, Tsai JN, Chen CJ, Ou CC, Wu WJ, Sheu GT, Ko JL.

J Cell Physiol · research support, non-u.s. gov't; journal article · DOI 10.1002/jcp.29924

Bibliografisk träff 2020-07-01

Anti-allergic effect of the Src family kinase inhibitor saracatinib.

Yamaki K, Terashi M, Ogura S, Inoue S, Naka N, Nakagaki T, Oka N, Koyama Y.

Pharmazie · journal article · DOI 10.1691/ph.2020.9949

Bibliografisk träff 2020-05-22

Biophysical and computational view on the <i>in vitro</i> combination between an anticancer drug, saracatinib and human serum albumin.

Tayyab S, Magesvaran MKA, Kabir MZ, Ridzwan NFW, Mohamad SB.

J Biomol Struct Dyn · journal article · DOI 10.1080/07391102.2020.1766571

Bibliografisk träff 2020-05-01

Targeting c-Src Reverses Accelerated GPX-1 mRNA Decay in Chronic Obstructive Pulmonary Disease Airway Epithelial Cells.

Dabo AJ, Ezegbunam W, Wyman AE, Moon J, Railwah C, Lora A, Majka SM, Geraghty P, Foronjy RF.

Am J Respir Cell Mol Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1165/rcmb.2019-0177oc

Bibliografisk träff 2020-04-30

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.

Baird K, Glod J, Steinberg SM, Reinke D, Pressey JG, Mascarenhas L, Federman N, Marina N, Chawla S, Lagmay JP, Goldberg J, Milhem M, Loeb DM, Butrynski JE, Turpin B, Staddon A, Spunt SL, Jones RL, Rodler ET, Schuetze SM, Okuno SH, Helman L.

Sarcoma · research-article; journal article · DOI 10.1155/2020/7935475

Bibliografisk träff 2020-02-12

Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.

Du G, Wang J, Zhang T, Ding Q, Jia X, Zhao X, Dong J, Yang X, Lu S, Zhang C, Liu Z, Zeng Z, Safadi R, Qi R, Zhao X, Hong Z, Lu Y.

Cell Death Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41419-020-2229-2

Bibliografisk träff 2020-01-13

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.

Liao X, Song G, Xu Z, Bu Y, Chang F, Jia F, Xiao X, Ren X, Zhang M, Jia Q.

BMC Cancer · research-article; journal article · DOI 10.1186/s12885-019-6480-9

Bibliografisk träff 2019-10-01

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM.

JAMA Neurol · research-article; journal article · DOI 10.1001/jamaneurol.2019.2050

Bibliografisk träff 2019-09-18

An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain.

Danson S, Mulvey MR, Turner L, Horsman J, Escott K, Coleman RE, Ahmedzai SH, Bennett MI, Andrew D.

J Bone Oncol · research-article; journal article · DOI 10.1016/j.jbo.2019.100261

Bibliografisk träff 2019-08-21

Synergistic effect of STAT3‑targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo.

Liu Q, Wang L, Li D, Zhao J, Chen S, Li J.

Mol Med Rep · research-article; journal article · DOI 10.3892/mmr.2019.10596

Bibliografisk träff 2018-12-07

The Fyn kinase inhibitor, AZD0530, suppresses mouse alcohol self-administration and seeking.

Morisot N, Berger AL, Phamluong K, Cross A, Ron D.

Addict Biol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1111/adb.12699

Bibliografisk träff 2018-05-24

Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.

Shin JS, Jung E, Kim M, Baric RS, Go YY.

Viruses · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.3390/v10060283

Bibliografisk träff 2018-03-31

LC-MS/MS reveals the formation of reactive ortho-quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling.

Attwa MW, Kadi AA, Darwish HW, Alrabiah H.

Clin Chim Acta · journal article · DOI 10.1016/j.cca.2018.03.037

Bibliografisk träff 2017-12-20

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.

McGivern N, El-Helali A, Mullan P, McNeish IA, Paul Harkin D, Kennedy RD, McCabe N.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.23524

Bibliografisk träff 2017-09-14

Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.

Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, Georg GI, Schönbrunn E.

J Med Chem · research-article; journal article · DOI 10.1021/acs.jmedchem.7b00996

Bibliografisk träff 2017-03-10

AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling.

Zhao Y, Yang Y, Xu Y, Lu S, Jian H.

FEBS Open Bio · research-article; journal article · DOI 10.1002/2211-5463.12162

Bibliografisk träff 2016-05-02

Discovery of Diverse Small-Molecule Inhibitors of Mammalian Sterile20-like Kinase 3 (MST3).

Olesen SH, Zhu JY, Martin MP, Schönbrunn E.

ChemMedChem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/cmdc.201600115

Bibliografisk träff 2015-11-01

Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment.

Bai J, Tu TY, Kim C, Thiery JP, Kamm RD.

Oncotarget · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.5464

Bibliografisk träff 2015-06-12

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.

Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C.

Invest New Drugs · clinical trial, phase ii; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-015-0257-z

Bibliografisk träff 2015-04-25

A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.

Gubens MA, Burns M, Perkins SM, Pedro-Salcedo MS, Althouse SK, Loehrer PJ, Wakelee HA.

Lung Cancer · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1016/j.lungcan.2015.04.008

Bibliografisk träff 2014-03-01

Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.

Geraghty P, Hardigan A, Foronjy RF.

Am J Respir Cell Mol Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1165/rcmb.2013-0258oc

Bibliografisk träff 2012-11-15

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Gangadhar TC, Clark JI, Karrison T, Gajewski TF.

Invest New Drugs · clinical trial, phase ii; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-012-9897-4